Abstract
Clozapine is an atypical neuroleptic used to manage treatment-resistant schizophrenia which is known to inhibit cardiac hERG/KV11.1 potassium channels, a pharmacological property associated with increased risk of potentially fatal Torsades de Pointes (TdP) and sudden cardiac death (SCD). Yet, the long-standing clinical practice of clozapine does not show a consistent association with increased incidence of TdP, although SCD is considerably higher among schizophrenic patients than in the general population. Here, we have established the inhibitory profile of clozapine at the seven cardiac ion currents proposed by the ongoing comprehensive in vitro pro-arrhythmia (CiPA) initiative to better predict new drug cardio-safety risk. We found that clozapine inhibited all CiPA currents tested with the following rank order of potency: KV11.1 > NaV1.5 (late current) ≈ CaV1.2 ≈ NaV1.5 (peak current) ≈ KV7.1 > KV4.3 > Kir2.1 (outward current). Half-maximal inhibitory concentrations (IC50) at the repolarizing KV11.1 and KV7.1 channels, and at the depolarizing CaV1.2 and NaV1.5 channels fell within a narrow half-log 3–10 µM concentration range, suggesting that mutual compensation could explain the satisfactory arrhythmogenic cardio-safety profile of clozapine. Although the IC50 values determined herein using an automated patch-clamp (APC) technique are at the higher end of clozapine plasmatic concentrations at target therapeutic doses, this effective antipsychotic appears prone to distribute preferentially into the cardiac tissue, which supports the clinical relevance of our in vitro pharmacological findings.
Similar content being viewed by others
Data availability
All data are included as a supplemental Prism file.
References
Adamantidis MM, Kerram P, Dupuis BA (1994) In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fundam Clin Pharmacol 8:391–407
Ballet V, Bohme GA, Brohan E, Boukaiba R, Chambard JM, Angouillant-Boniface O, Carriot T, Chantoiseau C, Fouconnier S, Houtmann S, Prevost C, Schombert B, Schio L, Partiseti M (2022) In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine. Eur J Pharmacol 915:174670
Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC (2013) QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 54:1–13
Christ T, Wettwer E, Ravens U (2005) Risperidone-induced action potential prolongation is attenuated by increased repolarization reserve due to concomitant block of I(Ca, L). Naunyn Schmiedebergs Arch Pharmacol 371:393–400
Crumb WJ Jr, Ekins S, Sarazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM Jr (2006) Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res 23:1133–1143
Darpo B (2010) The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 159:49–57
De Berardis D, Rapini G, Olivieri L, Di Nicola D, Tomasetti C, Valchera A, Fornaro M, Di Fabio F, Perna G, Di Nicola M, Serafini G, Carano A, Pompili M, Vellante F, Orsolini L, Martinotti G, Di Giannantonio M (2018) Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf 9:237–256
Dessertenne F (1966) Ventricular tachycardia with 2 variable opposing foci. Arch Mal Coeur Vaiss 59:263–272
Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA (1998) Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 18:477–481
Gintant G, Sager PT, Stockbridge N (2016) Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov 15:457–471
Grande I, Pons A, Baeza I, Torras A, Bernardo M (2011) QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. Hum Psychopharmacol 26:397–403
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mossner R, Muller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51:e1
Hou PY, Hung GC, Jhong JR, Tsai SY, Chen CC, Kuo CJ (2015) Risk factors for sudden cardiac death among patients with schizophrenia. Schizophr Res 168:395–401
Houtmann S, Schombert B, Sanson C, Partiseti M, Bohme GA (2017) Automated patch-clamp methods for the hERG cardiac potassium channel. Methods Mol Biol 1641:187–199
Kang UG, Kwon JS, Ahn YM, Chung SJ, Ha JH, Koo YJ, Kim YS (2000) Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 61:441–446
Kramer I, Rauber-Luthy C, Kupferschmidt H, Krahenbuhl S, Ceschi A (2010) Minimal dose for severe poisoning and influencing factors in acute human clozapine intoxication: a 13-year retrospective study. Clin Neuropharmacol 33:230–234
Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM (2013) MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci Rep 3:2100
Le Marois M, Ballet V, Sanson C, Maizieres MA, Carriot T, Chantoiseau C, Partiseti M, Bohme GA (2020) Cannabidiol inhibits multiple cardiac ion channels and shortens ventricular action potential duration in vitro. Eur J Pharmacol 886:173542
Lee SY, Kim YJ, Kim KT, Choe H, Jo SH (2006) Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br J Pharmacol 148:499–509
Meltzer, H.Y., Alphs, L., Green, A.I., Altamura, A.C., Anand, R., Bertoldi, A., Bourgeois, M., Chouinard, G., Islam, M.Z., Kane, J., Krishnan, R., Lindenmayer, J.P., Potkin, S. & International Suicide Prevention Trial Study, G (2003) Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry 60:82–91
Okhuijsen-Pfeifer C, Huijsman EAH, Hasan A, Sommer IEC, Leucht S, Kahn RS, Luykx JJ (2018) Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand 138:281–288
Risgaard B, Waagstein K, Winkel BG, Jabbari R, Lynge TH, Glinge C, Albert C, Correll CU, Haunso S, Fink-Jensen A, Tfelt-Hansen J (2015) Sudden cardiac death in young adults with previous hospital-based psychiatric inpatient and outpatient treatment: a nationwide cohort study from Denmark. J Clin Psychiatry 76:e1122-1129
Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350:1013–1022
Ruppert J, Hartung D, Westhoff-Bleck M, Herrmann J, Stubbs B, Cordes J, Kruger THC, Lichtinghagen R, Kahl KG (2018) Increased pericardial adipose tissue and cardiometabolic risk in patients with schizophrenia versus healthy controls. Eur Arch Psychiatry Clin Neurosci 268:719–725
Salvo, F., Pariente, A., Shakir, S., Robinson, P., Arnaud, M., Thomas, S., Raschi, E., Fourrier-Reglat, A., Moore, N., Sturkenboom, M., Hazell on behalf of investigators of the aritmo consortium, L. & Investigators of the, A.C (2016) Sudden cardiac and sudden unexpected death related to antipsychotics: a meta-analysis of observational studies. Clin Pharmacol Ther 99:306–314
Schwartz PJ, Woosley RL (2016) Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol 67:1639–1650
Titier K, Canal M, Deridet E, Abouelfath A, Gromb S, Molimard M, Moore N (2004) Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 199:52–60
Vohra J (2020) Sudden cardiac death in schizophrenia: a review. Heart Lung Circ 29:1427–1432
Warner B, Hoffmann P (2002) Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev 21:189–203
Acknowledgements
The authors are grateful to Fiona Ducrey for the language revision.
Funding
This study was funded by Sanofi R&D.
Author information
Authors and Affiliations
Contributions
MLM, CS, and MAM performed the research and analyzed the data. MP and GAB conceived and supervised the project. GAB wrote the article. All authors read and approved the manuscript.
Corresponding author
Ethics declarations
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Competing interests
All authors are current or former Sanofi employees and may hold shares and/or stock options in the company.
Disclaimer
The authors declare that all data were generated in-house and that no paper mill was used.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Le Marois, M., Sanson, C., Maizières, MA. et al. The atypic antipsychotic clozapine inhibits multiple cardiac ion channels. Naunyn-Schmiedeberg's Arch Pharmacol 396, 161–166 (2023). https://doi.org/10.1007/s00210-022-02314-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-022-02314-3